Stock Markets August 6, 2026 06:06 AM

SpaceX Shares Edge Higher Ahead of Staggered Lock-Up Expiration

Stock steadies as investors weigh potential insider selling after blockbuster earnings and mixed market signals

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
SPCX

Space Exploration Technologies Corp stock rose 1.3% in pre-market trading to $109.65 as investors positioned for a scheduled lock-up expiration that will make up to 20% of restricted shares eligible to trade. The move follows the company's first quarterly report as a public company showing $7.8 billion in Q2 revenue and an $18.4 billion capital expenditure charge that coincided with a net loss of $541 million and heavy after-hours selling.

SpaceX Shares Edge Higher Ahead of Staggered Lock-Up Expiration
SPCX
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Space Exploration Technologies shares rose 1.3% in pre-market trading to $109.65 as investors anticipated a lock-up expiration that will make up to 20% of restricted shares tradable - markets impacted: equities, technology and aerospace sectors.
  • Q2 results showed $7.8 billion in revenue, up 92% year-over-year, but headlines focused on an $18.4 billion capital expenditure figure and a $541 million net loss - markets impacted: equity valuation and analyst coverage in technology and growth stocks.
  • Analysts broadly maintained bullish stances with an average 12-month price target near $223, while the staggered nature of the lock-up release and extended executive lock-ups until 2027 provided some relief to immediate selling concerns - markets impacted: investor sentiment and secondary share supply dynamics.

Space Exploration Technologies Corp shares ticked up 1.3% in pre-open trading, trading at $109.65, as market participants prepared for a lock-up expiration that could bring insider sales into the market. Beginning Thursday, as much as 20% of the firm's restricted shares will become eligible to trade, a development investors are watching closely.


The company published its first quarterly earnings report as a public entity after the close on August 4. Results for the second quarter showed revenue of $7.8 billion, a rise of 92% year-over-year and notably above consensus. However, the report was dominated by an $18.4 billion capital expenditure figure and a net loss of $541 million, outcomes that triggered a sharp decline in the stock in after-hours and pre-market sessions on August 5.

Following the earnings-induced sell-off, a number of Wall Street firms moved to defend the shares. JPMorgan increased its price target to $240 from $225. Mizuho reiterated an Outperform rating with a $200 target. Both RBC Capital and Deutsche Bank held Buy ratings with $225 targets. Across analysts, the average 12-month price target sits roughly at $223, suggesting substantial upside from the prevailing share price.


Part of the calmer tone in early trading reflects the specific structure of the lock-up expiration. Although the event potentially frees up to 911.5 million insider shares, the release is staggered. Several senior executives, including the chief financial officer and chief operating officer, placed their holdings under extended lock-up arrangements or trading plans that do not commence until 2027. That sequencing has eased concerns that a sudden wave of selling will hit the market immediately.

Traders pointed to a mix of dip-buying, the wave of analyst support after earnings, and the recognition that any selling pressure from the lock-up may unfold gradually rather than all at once as reasons the stock found modest footing. Nevertheless, longer-term uncertainty remains. The company's trajectory for AI-related spending and questions around a supply overhang continue to weigh on sentiment among market participants.


The broader market backdrop was mixed on the session that saw SpaceX stabilize. The S&P 500 inched up 0.2% and the Dow Jones added 0.3%, while the NASDAQ slipped 0.3%, a pattern that reflects lingering caution in the technology sector. Space Exploration Technologies' 52-week trading range of $104.83 to $225.64 highlights the dramatic repricing the stock has experienced since its record-breaking June IPO, which priced at $135 per share.

In sum, a combination of tactical buying, analyst reinforcement and the staggered nature of the lock-up expiration allowed the stock to trade marginally higher in pre-market activity, even as ongoing debates about capital allocation and inventory risk remain part of the longer-term discussion among investors and analysts.


Market snapshot and notable figures:

  • Pre-open move: +1.3% to $109.65
  • Q2 revenue: $7.8 billion, up 92% year-over-year
  • Capital expenditures reported: $18.4 billion
  • Net loss: $541 million
  • Potential insider shares becoming eligible: up to 20% of restricted shares, or up to 911.5 million shares
  • Analyst 12-month average price target: ~ $223
  • 52-week range: $104.83 to $225.64

Editor review noted.

Risks

  • Lock-up expiration could increase supply as up to 20% of restricted shares become eligible to trade, potentially pressuring the stock if selling accelerates - sectors affected include equities and investor liquidity in the technology and aerospace space.
  • Significant capital expenditures of $18.4 billion and a reported net loss of $541 million raise concerns about the company's near-term profitability and spending trajectory, including AI-related investments, which remain a focal point for investors - sectors affected include technology and capital markets.
  • Ongoing worries about a potential supply overhang could continue to weigh on sentiment despite short-term stabilization, creating uncertainty for market participants and impacting trading volumes in the stock.

More from Stock Markets

Howmet Aerospace Stock Jumps After Strong Q2 Results and Raised Guidance Aug 6, 2026 Datadog Shares Plunge Pre-Market Despite Beat-and-Raise Quarter Aug 6, 2026 Unity Shares Rally After Strong Q2 Results and Upbeat Q3 Guidance Aug 6, 2026 Constellation Energy Jumps After Q2 Results and Board Changes Aug 6, 2026 Insmed Shares Leap After Q2 Results and Bullish Brinsupri Guidance Aug 6, 2026